Data as of .
BBC vs PBE: which is really different?
BBC and PBE hold 2% of their weight in the same names, and BBC returned more over the year.
ETFIQ Off-Index Score: BBC scores higher
How much of it is not the index it is sold as an alternative to?
A percentile among the 379 thematic ETFs with a holdings filing. It is a position in a set, not a rating, and neither end of it is a recommendation. All thematic ETFs ranked by it · How it is computed
2% of the two portfolios are the same securities at the same weight.
What they hold in common
By the books each fund has filed, BBC and PBE hold 2% of their money in the same securities at the same weight.
| Holding | BBC | PBE |
|---|---|---|
| ANAPTYSBIO INC | 1.08% | 2.68% |
| PROTAGONIST THERAPEUTICS INC | 0.77% | 2.69% |
| Only in BBC | Only in PBE |
|---|---|
| ERASCA INC 2.19% | Natera Inc 5.70% |
| ENLIVEN THERAPEUTICS INC 1.81% | Illumina Inc 5.53% |
| TANGO THERAPEUTICS INC 1.71% | Gilead Sciences Inc 5.27% |
| ORUKA THERAPEUTICS INC 1.68% | Biogen Inc 5.07% |
| SPYRE THERAPEUTICS INC 1.64% | Regeneron Pharmaceuticals Inc 4.89% |
| ALUMIS INC 1.59% | Royalty Pharma PLC 4.88% |
| DIANTHUS THERAPEUTICS INC 1.54% | Vertex Pharmaceuticals Inc 4.77% |
| KODIAK SCIENCES INC 1.35% | Amgen Inc 4.53% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Apr 30, 2026 and Sep 19, 2026.
Performance, window by window
| Window | Total return | vs the S&P 500 | vs the Nasdaq-100 | |||
|---|---|---|---|---|---|---|
| BBC | PBE | BBC | PBE | BBC | PBE | |
| 3 months | +6.9% | +13.2% | +4.7 pts | +11.0 pts | +9.4 pts | +15.7 pts |
| 6 months | +22.7% | +25.9% | +4.7 pts | +7.8 pts | −1.5 pts | +1.6 pts |
| 1 year | +95.6% | +36.2% | +79.0 pts | +19.6 pts | +73.8 pts | +14.4 pts |
| 3 years | +143.8% | +65.0% | +65.3 pts | −13.4 pts | +45.6 pts | −33.1 pts |
| Since launch | +92.6% | +492.4% | −268.5 pts | −311.1 pts | −583.0 pts | −1197.8 pts |
| BBC Virtus Biotech Clinical Trials ETF Holds 124 stocks in biotech, 0% of its weight in S&P 500 companies | PBE Invesco Biotechnology & Genome ETF Holds 33 stocks in biotech, 30% of its weight in S&P 500 companies | |
|---|---|---|
| Issuer | Virtus | Invesco |
| Theme | Biotech | Biotech |
| In the S&P 500 | 0.0% | 30.0% |
| Active share vs the S&P 500 | 100.0% | 99.0% |
| In the Nasdaq-100 | 0.0% | 19.5% |
| Holdings | 124 | 33 |
| Top ten, share of the fund | 16.2% | 46.7% |
| Expense ratio | 0.65% | 0.59% |
| Fee for the differing part | 0.65% | 0.60% |
| Total return, 1 year | +95.6% | +36.2% |
| vs the S&P 500 | +79.0 pts | +19.6 pts |
| vs the Nasdaq-100 | +73.8 pts | +14.4 pts |
| Below its high | −19.1% | −3.9% |
| Net assets | $37m | $414m |
BBC in plain words
By weight, 0% of BBC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 16% of the fund across 124 positions, as filed for Apr 30, 2026. Over the year to Sep 18, 2026 the fund returned +95.6% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 79.0 pts. It sits 19.1% below its all-time high of Feb 8, 2021.
PBE in plain words
By weight, 30% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 47% of the fund across 33 positions, as published by its issuer for Sep 19, 2026. Over the year to Sep 18, 2026 the fund returned +36.2% with distributions reinvested against +16.6% for the S&P 500, so a holder was ahead by 19.6 pts.
Questions people ask
- Do BBC and PBE hold the same stocks?
- By their latest filings, 2% of their books are the same securities at the same weight, which is mostly different names. Overlap is the sum of the smaller weight of every security they share.
- Which is more different from the S&P 500, BBC or PBE?
- BBC has 0% of its weight in S&P 500 names and PBE has 30%, so BBC differs more from the index.
- Which is cheaper, BBC or PBE?
- BBC charges 0.65% a year and PBE charges 0.59%, so PBE is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, BBC against PBE, data as of Sep 18, 2026. https://etfiq.com/compare/themes/bbc-vs-pbe Free to use with attribution; the underlying files are at Open data.